Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a weekly shot help people with obesity shed significant weight?

NCT ID NCT07794761

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This Phase 3 trial tests an investigational drug called berobenatide, given as a once-weekly injection, in about 180 adults with obesity in Japan. Some participants may also have type 2 diabetes. Researchers randomly assign participants to receive either berobenatide or a placebo for about 22 months, then compare changes in body weight and other health measures to see if the drug helps with weight loss and is safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
berobenatide (also known as MET097, PF-08653944), an investigational drug given as a weekly injection
What this could lead to
If it works, berobenatide could offer a new once-weekly treatment option to help people with obesity achieve meaningful weight loss and improve related health conditions.
What could go wrong
This is an early-stage test in a specific group of adults in Japan, and the drug may not prove more effective than placebo. As with any weight-loss medication, there may be side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥18 years. * BMI of: ≥27.0 kg/m2 to \<35.0 kg/m2 with ≥2 obesity-related health disorders or BMI of ≥35.0 kg/m2 with ≥1 obesity-related health disorder. The participant must have at least one of either hypertension, dyslipidemia or glucose intolerance (T2D and impaired glucose tolerance etc.) as an obesity-related health disorder. Exclusion Criteria: * Have a self-reported body weight change greater than 5% within 90 days prior to Screening. * Diagnosis of type 1 diabetes or any other form of diabetes other than T2D. * History of acute or chronic pancreatitis. * Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    12 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Doujin Memorial Foundation Meiwa Hospital

    Chiyoda-ku, Tokyo, 101-0041, Japan

  • Fukuwa Clinic

    Chuo-ku, Tokyo, 104-0031, Japan

  • Higashi-Shinjuku Clinic, Keikokai Medical Corp.

    Shinjuku-ku, Tokyo, 169-0072, Japan

  • Ikebukuro Metropolitan Clinic

    Toshima-ku, Tokyo, 171-0021, Japan

  • Manda Memorial Hospital

    Sapporo, Hokkaido, 060-0062, Japan

  • Medical Corporation Heishinkai OCROM Clinic

    Suita, Osaka, 565-0853, Japan

  • Medical Corporation Heishinkai ToCROM Clinic

    Shinjuku-ku, Tokyo, 160-0008, Japan

  • Nihonbashi Sakura Clinic

    Tokyo, 103-0025, Japan

  • Oishi Clinic

    Kasuya-gun, Fukuoka, 811-2310, Japan

  • Shimamura Memorial Hospital

    Nerima-ku, Tokyo, 177-0051, Japan

  • Tokyo Center Clinic

    Chuo-ku, Tokyo, 103-0027, Japan

  • Tokyo-Eki Center-building Clinic

    Chuo-ku, Tokyo, 103-0027, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.